| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sNDA Submission example | sNDA | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
sNDA Submission example | sNDA | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
sNDA Submission example | sNDA | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
Insmed Incorporated$115.61
-3.16 (-2.67%)
B 63Pipeline Score Overvalued Pharma · Commercial
Market Cap
23.03 B
EPS
-5.74
P/E Ratio
-
Value Trade
308.45 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
305.96 M
R&D Expenses
209.49 M
Operating CF
-222.74 M
Total Assets
2.08 B
Total Liabilities
1.37 B
Equity
704.85 M
D/E Ratio
12,345
-7.05 %
Week
-25.39 %
1 Month
-32.93 %
3 Month
-46.64 %
6 Month
299.55 %
5 Year
-33.6 %
All Time
Cash Data
Cash Position
1.22 B
Monthly Burn
74.25 M
Runway
14.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.93 M
52 Week Range
65.56 - 212.75
% held by Insiders
0.95 %
% held by Institutions
101.83 %
Enterprise Value
22.55 B
Total Shares
215.49 M
Short %
7.52 %
Float Shares
213.12 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Insmed Incorporated
724Total events
5Upcoming
179Tier-1 (high impact)
2010 – 2035Coverage
Upcoming catalysts 5
TBD
T2Trial Initiation
Insmed plans to advance Phase 2 development program for INS1148 in moderate-to-severe asthma
Event history 719
Q3 2026
◆sNDA SubmissionARIKAYCEApprovedRegulatory Filing
Planned sNDA submission for ARIKAYCE label expansion in U.S.
MAC lung diseasesource ↗
Q3 2026
◆PMDA MilestoneARIKAYCEApprovedEx-US Regulatory
Planned submission to PMDA for label expansion in Japan
MAC lung diseasesource ↗
Jun 25, 2026
▲Partnership / LicensebrensocatibApprovedCorporate
EMBARC announces intention to collaborate with Insmed on interventional study of brensocatib
bronchiectasissource ↗
Jun 23, 2026
◆Management ChangeCorporate
Appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Jun 9, 2026
◆Oral PresentationPresentation
Insmed management to present at 2026 Goldman Sachs Annual Global Healthcare Conference
May 20, 2026
May 19, 2026
◆Poster PresentationPresentation
Data highlighting disease burden in PH-ILD at ATS 2026
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
May 18, 2026
◆Oral PresentationBRINSUPRIApprovedPresentation
Post-hoc analysis from Phase 3 ASPEN trial of BRINSUPRI at ATS 2026
non-cystic fibrosis bronchiectasis (NCFB)source ↗
May 18, 2026
◆Poster PresentationBRINSUPRIApprovedPresentation
Real-world experience data in NCFB patients at ATS 2026
non-cystic fibrosis bronchiectasis (NCFB)source ↗
May 18, 2026
◆Poster PresentationTPIPPresentation
Pharmacokinetic analysis of TPIP at ATS 2026
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
May 17, 2026
◆Late-BreakerARIKAYCEApprovedPresentation
Late-breaking ARIKAYCE results from Phase 3b ENCORE study at ATS 2026
Mycobacterium avium complex (MAC) lung infectionsource ↗
May 12, 2026
Drug Pipeline Intelligence
B63
Pipeline Score $4.8B
Pipeline ValueOvervalued
Valuation Signal12
Drugs Scored0.3x
rNPV / MCap Top 90%
Mid Cap (rank 92 of 911)
Percentile RankInsmed Incorporated holds a solid B-grade pipeline (63/100), with $5.6B risk-adjusted pipeline value, led by Liposomal amikacin for in Cystic Fibrosis (Phase 3), across $123B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liposomal amikacin for Small molecule | Cystic Fibrosis | Phase 3 | NCT01316276 | 58% | $1.8B | COMPLETED | 206 | - | - | Jul 16, 2015 | - | Jun 17, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
brensocatib BreakthroughPriority | hidradenitis suppurativa | Phase 2b | 2026-04-07 | 10 mg reduction: 45.5%; 40 mg reduction: 40.3%; placebo reduction: 57.1% Read More | Insmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety Sign Read More | |
brensocatib BreakthroughPriority | hidradenitis suppurativa | Phase 2b | 2026-04-07 | 10 mg reduction: 45.5%; 40 mg reduction: 40.3%; placebo reduction: 57.1% Read More | Insmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety Sign Read More | |
brensocatib BreakthroughPriority | hidradenitis suppurativa | Phase 2b | 2026-04-07 | 10 mg reduction: 45.5%; 40 mg reduction: 40.3%; placebo reduction: 57.1% Read More | Insmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety Sign Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INSM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INSM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INSMEMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
EMBARC has announced a collaboration with Insmed to conduct a landmark study on brensocatib's potential to modify bronchiectasis disease progression. The long-term, open-label study will enroll approximately 3,000 patients across Europe, aiming to evaluate the drug's effects on lung function decline and exacerbation frequency. This research builds on previous trial data and seeks to determine if earlier intervention can significantly change disease outcomes.
Read more →INSMInsmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Insmed has appointed Samuele Butera as Senior Vice President and General Manager of Global Respiratory. With over two decades of experience in commercial leadership, Butera will oversee Insmed's Respiratory Therapeutic Area. His previous roles include significant positions at Johnson & Johnson and Novartis, where he led successful product launches and expansions.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 103 new employees under its 2025 Inducement Plan, as part of Nasdaq Listing Rule 5635(c)(4). The awards include 97,091 restricted stock units and options to purchase 12,850 shares of common stock, all of which have a specific vesting schedule designed to enhance employee retention. This initiative underscores Insmed's commitment to attracting talent to support its ongoing development of innovative therapies for serious diseases.
Read more →INSMInsmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Insmed Incorporated will present at the 2026 Goldman Sachs Annual Global Healthcare Conference on June 9, 2026. The event will be webcast live and archived for 30 days. Insmed focuses on delivering innovative therapies for serious diseases and has been recognized as a top employer in the biopharmaceutical sector.
Read more →INSM▼ -23.4%on this news
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Insmed reported a strong financial performance for Q1 2026, with total revenues of $306 million. BRINSUPRI revenues increased significantly, while ARIKAYCE also showed modest growth. The company reiterated its revenue guidance for both products and announced the initiation of a Phase 3 study for TPIP. Positive results from the ENCORE study further bolster Insmed's growth prospects.
Read more →INSM▼ -23.4%on this newsshared move
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
Insmed has partnered with Ty Pennington to launch the Suspect Bronchiectasis initiative, aimed at increasing awareness and proper diagnosis of bronchiectasis. This chronic lung disease often goes unrecognized due to symptom overlap with conditions like COPD and asthma. The initiative encourages patients with unresolved respiratory issues to consult pulmonologists for further testing.
Read more →INSM▲ +5.1%on this news· ran to -21% by day 3shared move
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
Insmed Incorporated will present six abstracts from its respiratory portfolio at the ATS 2026 conference, including late-breaking results from the Phase 3b ENCORE study on ARIKAYCE. The conference will highlight the company's commitment to addressing serious pulmonary conditions and improving bronchiectasis diagnosis through an independent research grant. The findings aim to showcase the potential of ARIKAYCE in treating Mycobacterium avium complex lung disease.
Read more →INSMInsmed to Present at May 2026 Investor Conferences
Insmed Incorporated announced its participation in two upcoming investor conferences in May 2026. The BofA Securities Healthcare Conference will take place in Las Vegas, while the RBC Capital Markets Global Healthcare Conference will be held in New York City. Both events will be webcast live, allowing broader access to the company's updates.
Read more →INSMInsmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
Insmed Incorporated will release its first-quarter 2026 financial results on May 7, 2026. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can participate by phone or via a live webcast on Insmed's website.
Read more →INSMInsmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety Sign
Insmed Incorporated announced that the Phase 2b CEDAR study evaluating brensocatib for moderate to severe hidradenitis suppurativa failed to meet its primary and secondary efficacy endpoints. As a result, Insmed will discontinue the development of brensocatib for this indication. Although the drug was well-tolerated and no new safety signals were found, the study's outcomes were disappointing, with lower reductions in abscess and inflammatory nodule counts compared to the placebo. Insights from this study may aid in advancing the scientific understanding of hidradenitis suppurativa.
Read more →INSM▲ +5.9%on this news
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
Insmed announced positive topline results from the Phase 3b ENCORE study of ARIKAYCE in patients with MAC lung disease. The study met its primary and secondary endpoints, showing significant improvements in respiratory symptoms and culture conversion rates. Insmed plans to file a supplemental NDA with the FDA and submit data to the PMDA in Japan in late 2026 to support potential label changes.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated announced the granting of inducement awards to 85 new employees as part of its 2025 Inducement Plan. The awards include restricted stock units and stock options, aimed at attracting talent under Nasdaq Listing Rule 5635(c)(4). The company emphasizes its commitment to employee satisfaction and its status as a leading employer in the biopharmaceutical sector.
Read more →INSM▲ +6.5%on this news
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update -Company Expects Full-Year 2026 BRINSUPRI (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAY
Insmed Incorporated reported its financial results for 2025, highlighting a total revenue of $606.4 million. The company anticipates that revenues from its product BRINSUPRI will reach at least $1 billion in 2026, alongside a projected $450-$470 million from ARIKAYCE. Positive developments include exceeding revenue expectations for ARIKAYCE and maintaining strong cash reserves. However, the company also posted a substantial net loss for the year, underscoring ongoing financial challenges.
Read more →INSMInsmed To Present at March 2026 Investor Conferences
Insmed Incorporated announced its participation in several investor conferences scheduled for March 2026. The events will be webcast live, allowing broader access to investors and stakeholders. Insmed is focused on delivering innovative therapies for serious diseases and has a strong portfolio in pulmonary and inflammatory conditions.
Read more →INSMInsmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
Insmed Incorporated will release its fourth-quarter and full-year 2025 financial results on February 19, 2026. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested participants can join via phone or webcast, with a replay available for a limited time.
Read more →INSMInsmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
Insmed Incorporated will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the PVRI 2026 congress in Dublin. The presentations will cover the Phase 3 PALM-PAH study design and topline results from the Phase 2b study, along with new imaging analysis and preclinical data. Insmed aims to establish TPIP as a leading therapy for pulmonary arterial hypertension.
Read more →INSMInsmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Insmed provided a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting strong revenue growth for its products, including BRINSUPRI and ARIKAYCE. The company anticipates significant clinical data releases in 2026, which could further enhance its portfolio. However, the preliminary financial results for 2025 are subject to adjustments, and there are risks associated with regulatory approvals.
Read more →INSMInsmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
Insmed Incorporated announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The presentation will showcase the company's commitment to developing innovative therapies for serious diseases. The event will be webcast live and archived for later access, highlighting Insmed's ongoing advancements in biopharmaceuticals.
Read more →INSM▼ -16.1%on this news
Insmed Provides Clinical and Business Update
Insmed announced that the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps failed to meet its efficacy endpoints, leading to the discontinuation of the program. Despite this setback, the company has acquired INS1148, a monoclonal antibody aimed at respiratory and inflammatory diseases, which they plan to advance into Phase 2 trials.
Read more →INSMInsmed Provides Clinical and Business Update -Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Progra
Insmed announced the disappointing results of its Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP), stating it failed to meet primary and secondary efficacy endpoints. As a result, the company has decided to discontinue its development program for this indication. On a more positive note, Insmed also revealed the acquisition of INS1148, a monoclonal antibody that may offer new treatment options for respiratory and immunological conditions.
Read more →INSMEuropean Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
The European Commission has approved BRINSUPRI (brensocatib) as the first treatment for non-cystic fibrosis bronchiectasis (NCFB) in the EU. This first-in-class therapy was reviewed under the EMA's accelerated assessment pathway due to its significance for public health. Clinical trials demonstrated a notable reduction in exacerbations and lung function decline among patients. Insmed plans to ensure access for eligible patients starting in early 2026.
Read more →INSMInsmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
Insmed Incorporated held its fourth annual Global Day of Good, with over 1,200 employees volunteering across the U.S., Europe, and Japan. This year's event focused on various community support initiatives, including meal preparation and educational projects. Insmed's commitment to corporate responsibility was highlighted, showcasing the positive impact of employee engagement in local communities.
Read more →INSMInsmed To Present at November and December 2025 Investor Conferences
Insmed Incorporated announced its participation in upcoming investor conferences in November and December 2025. The events will be webcast live, allowing broader access to the company's presentations. Insmed continues to focus on delivering innovative therapies for serious diseases, with a strong emphasis on patient care and advanced drug discovery.
Read more →INSM▲ +16.3%on this news
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
Insmed Incorporated reported its third-quarter 2025 financial results, highlighting the FDA approval of BRINSUPRI for non-cystic fibrosis bronchiectasis. The company achieved total revenues of $28.1 million for BRINSUPRI and $114.3 million for ARIKAYCE, reflecting a 22% growth year-over-year. Insmed raised its revenue guidance for ARIKAYCE and anticipates significant clinical milestones in the upcoming months. Despite these successes, the company reported a substantial operating loss and increased expenses.
Read more →INSMInsmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
Insmed Incorporated has been recognized as the top employer in Science's 2025 Top Employers Survey for the fifth year in a row. The survey, which gathered responses from over 5,500 employees, highlighted Insmed's strong corporate image, leadership, and work culture. The company's growth is attributed to its commitment to developing therapies for serious diseases. Insmed's CEO and Chief People Strategy Officer expressed pride in the recognition and the company's people-first culture.
Read more →INSMCHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced that the European Medicines Agency's CHMP has recommended approval for BRINSUPRI (brensocatib) to treat non-cystic fibrosis bronchiectasis in patients aged 12 and older. If approved, BRINSUPRI will be the first-in-class therapy for this condition in the EU. The recommendation follows data from clinical studies showing its efficacy and safety. This milestone could greatly enhance treatment options for patients suffering from this progressive disease.
Read more →INSMInsmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
Insmed Incorporated announced it will present six abstracts from the Phase 3 ASPEN study of BRINSUPRI at the CHEST 2025 meeting. The presentations will cover various analyses, including efficacy, symptom reduction, and the drug's mechanism of action in treating non-cystic fibrosis bronchiectasis. This marks a significant opportunity for Insmed to showcase its research following the FDA approval of BRINSUPRI.
Read more →INSMInsmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
Insmed Incorporated announced it will release its third-quarter 2025 financial results on October 30, 2025. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can join via phone or webcast, with a replay available for a limited time.
Read more →INSMInsmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) will present seven abstracts from its late-stage portfolio at the European Respiratory Society Congress 2025. Key highlights include data from a Phase 2b study of Treprostinil Palmitil Inhalation Powder for pulmonary arterial hypertension and subgroup analyses from the Phase 3 ASPEN trial of Brensocatib for non-cystic fibrosis bronchiectasis. The congress will take place in Amsterdam from September 27 to October 1, 2025, showcasing significant advancements in respiratory medicine.
Read more →INSMInsmed To Present at September Investor Conferences Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated has announced its participation in various investor conferences, which will be webcast live and archived for later access. The company is committed to developing first- and best-in-class therapies aimed at transforming the lives of patients with serious diseases. With a rich portfolio featuring approved and investigational medicines, Insmed is focused on addressing needs in pulmonary and inflammatory conditions. The company's innovative approaches include gene therapy, AI-driven protein engineering, and other advanced technologies.
Read more →INSM▲ +8.1%on this news
FDA Approves BRINSUPRI (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Br
Insmed announced the FDA approval of BRINSUPRI (brensocatib) for treating non-cystic fibrosis bronchiectasis, marking it as the first and only treatment for this chronic lung disease. Approximately 500,000 patients in the U.S. are affected, highlighting the significance of this approval. Clinical trials demonstrated that BRINSUPRI significantly reduces the rate of exacerbations and helps in maintaining lung function. Despite its benefits, some patients may experience adverse reactions such as upper respiratory infections and hypertension.
Read more →INSMInsmed Reports Second-Quarter 2025 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth
Insmed reported its financial results for the second quarter of 2025, revealing total revenue of $107.4 million for ARIKAYCE, representing a 19% growth year-over-year. The company is on track with the NDA submission for Brensocatib, targeting an FDA decision by August 12, 2025. Additionally, Insmed plans to initiate Phase 3 studies for TPIP later in 2025 and anticipates topline data from the Phase 2b BiRCh study by the end of 2025. Despite promising revenue growth and positive trial results, the company's net loss increased considerably, raising concerns about financial stability.
Read more →INSMInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated has announced the release of its second-quarter 2025 financial results, scheduled for August 7, 2025. The company will host a conference call for investors to discuss these results and provide a business update. Insmed is recognized for its commitment to delivering innovative therapies for serious diseases and has an extensive portfolio that includes various investigational medicines. The call will also be accessible via a live webcast and will be archived for later access.
Read more →INSM▲ +7.8%on this news
Insmed Announces Proposed $650 Million Public Offering of Common Stock BRIDGEWATER, N.J.
Insmed Incorporated announced its intention to offer and sell $650 million of common stock in an underwritten public offering. The offering is part of Insmed's shelf registration statement that was filed with the SEC, and the underwriters will have a 30-day option to purchase up to an additional $97.5 million of shares. While the funds are intended to support the company's diverse portfolio of therapies, the offering is subject to market conditions, which may pose risks regarding its successful completion. Additionally, maintaining the regulatory approval for their products remains a significant concern for the company.
Read more →INSM▲ +7.8%on this news
Insmed Announces Pricing of $750 Million Public Offering of Common Stock Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated has announced the pricing of its public offering of 7,812,500 shares at $96 each, aiming to raise approximately $750 million. The proceeds will fund ongoing research and development for its key products, including brensocatib and ARIKAYCE. The offering is managed by several financial institutions and is set to close on June 13, 2025, pending customary conditions. Insmed faces challenges including market conditions and regulatory approval processes for its products.
Read more →INSM▲ +28.7%on this news· ran to +40% by day 3shared move
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension -The Study Met Primary and All Second
Insmed announced positive topline results from a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) for treating pulmonary arterial hypertension (PAH). The study successfully met both its primary and secondary endpoints, showcasing effectiveness in reducing pulmonary vascular resistance and improving exercise capacity. 75% of patients tolerated the maximum dose well, and the company plans to discuss Phase 3 trial designs with the FDA, aiming for trials to start in late 2025. The overall results represent significant progress in developing a new therapy for PAH.
Read more →INSMInsmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced its participation in the 2025 Goldman Sachs Annual Global Healthcare Conference, scheduled for June 11, 2025, in Miami. The event will highlight Insmed's commitment to delivering innovative therapies for serious diseases and will be available via live webcast. The company, headquartered in Bridgewater, New Jersey, is recognized for its employee satisfaction and is actively developing a range of biopharmaceutical therapies for pulmonary and inflammatory conditions.
Read more →INSMBrensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated recently shared new findings from its Phase 3 ASPEN study of brensocatib, showcasing its effectiveness in reducing pulmonary exacerbations among diverse patient groups with non-cystic fibrosis bronchiectasis. The data presented at the ATS 2025 conference indicated that brensocatib demonstrated consistent efficacy and safety across defined subgroups, suggesting its potential as a primary therapy for a disease with no approved treatments. Alongside dethis, Insmed's portfolio was highlighted through several other abstracts detailing the impacts of their therapies on health outcomes and lung function.
Read more →INSMInsmed Reports First-Quarter 2025 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Ove
Insmed reported financial results for Q1 2025, revealing total revenue of $92.8 million which reflects a 23% increase from the previous year. The company continues to progress with its NDA for Brensocatib for bronchiectasis, ensuring the timeline is on track for a PDUFA action date of August 12, 2025. Additionally, they announced completion of a Phase 2b study for TPIP in pulmonary arterial hypertension (PAH) and have submitted MAA filings for Brensocatib to both EMA and MHRA. The company remains focused on achieving its revenue guidance of $405 million to $425 million for ARIKAYCE in 2025.
Read more →INSMInsmed To Present at the BofA Securities 2025 Health Care Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced its participation at the BofA Securities 2025 Health Care Conference in Las Vegas on May 13, 2025. The event aims to highlight the company's advancements in biopharmaceutical therapies, particularly for serious diseases. Insmed is recognized for its diverse portfolio of approved and investigational medicines, with a focus on innovative approaches including gene therapy and AI-driven protein engineering. Additionally, Insmed has been recognized as a top employer in the industry.
Read more →INSMInsmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 BRIDGEWATER, N.J.
Insmed Incorporated has announced the redemption of all $569.5 million of its outstanding 0.75% Convertible Senior Notes due 2028, effective June 6, 2025. Investors will receive a cash payment equivalent to 100% of the principal amount plus any accrued interest. Holders of the notes also have the option to convert their holdings into shares of common stock until June 4, 2025. This strategic move reflects the company's ongoing efforts to strengthen its financial position and support its growth objectives.
Read more →INSMNew England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed has announced positive results from the pivotal phase 3 ASPEN study of brensocatib for bronchiectasis, published in NEJM. The study demonstrated a statistically significant reduction in pulmonary exacerbations and slowed lung function decline in patients when compared to placebo. The findings are particularly notable as bronchiectasis currently has no approved therapies available. Brensocatib is under Priority Review by the FDA, with a target action date set for August 12, 2025.
Read more →INSMInsmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced its plan to release financial results for the first quarter of 2025 on May 8, 2025. The company will host a conference call for investors to discuss these results and provide a business update. This call will be accessible by phone as well as through a live webcast on Insmed's website, with a replay option available for a limited time afterward. Insmed is recognized for its commitment to developing innovative therapies aimed at serious diseases, particularly in pulmonary and inflammatory conditions.
Read more →INSMInsmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced that it will present 11 abstracts from its respiratory portfolio at the American Thoracic Society 2025 International Conference. Key topics include analyses from the Phase 3 ASPEN study on brensocatib, which evaluates its efficacy and safety across various subgroups. Other presentations will focus on health outcomes in patients with Mycobacterium Avium Complex lung disease and data from the Phase 2a study of TPIP for pulmonary hypertension. The conference will be held from May 18-21, 2025, in San Francisco.
Read more →INSMInsmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis -FDA Reaffirms Application is Under Priority Review wit
Insmed Incorporated has announced that the FDA does not currently plan to hold an advisory committee meeting regarding the New Drug Application for brensocatib, aimed at treating bronchiectasis. The FDA has reaffirmed the application is under Priority Review with a target action date set for August 12, 2025. Brensocatib, if approved, could become the first treatment specifically for bronchiectasis, based on data from a significant clinical study. Insmed expresses confidence in its ongoing dialog with the FDA as it seeks to bring this treatment to market.
Read more →INSMInsmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million fo
Insmed reported strong financial results for Q4 and the full year 2024, with a total revenue of $104.4 million in Q4, exceeding their guidance. The company also announced the acceptance of its NDA for Brensocatib by the FDA, which has been granted priority review, positioning it for potential market entry in August 2025. Insmed emphasized its commitment to delivering value through its evolving pipeline and projections for double-digit growth in ARIKAYCE revenues in 2025. However, the company faces significant operating and net losses that raise questions about its long-term financial health.
Read more →INSMInsmed To Present at March 2025 Investor Conferences Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) announced that its management will present at several investor conferences in March 2025. These presentations will be available via live webcast, with archives accessible for 30 days post-event. The company is known for its commitment to developing first- and best-in-class therapies, focusing on pulmonary and inflammatory diseases. Insmed continues to innovate with a wide range of advanced research programs in various therapeutic areas.
Read more →INSMInsmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated will release its financial results for the fourth quarter and full year of 2024 on February 20, 2025. The company's management will host a conference call to discuss these results and provide a business update. Insmed is recognized for its diverse portfolio of investigational medicines and has a strong focus on therapies for severe diseases, particularly in pulmonary and inflammatory conditions.
Read more →INSMFDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for
The FDA has granted Priority Review for Insmed's brensocatib, a potential first treatment for bronchiectasis, with a target action date of August 12, 2025. This follows promising results from the Phase 3 ASPEN study, which indicated significant efficacy in reducing exacerbation rates. If approved, brensocatib will also be the first drug in the new class of DPP1 inhibitors. Insmed plans to submit applications for approval in Europe, the UK, and Japan in 2025.
Read more →INSMInsmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference -ARIKAYCE (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenu
Insmed provided a business update at the 43rd J.P. Morgan Healthcare Conference, indicating that ARIKAYCE's global revenues for 2024 exceeded expectations at approximately $363.7 million. The company anticipates continued revenue growth for ARIKAYCE in 2025, projecting sales between $405 million and $425 million. Significant milestones include the submission of a NDA for Brensocatib, expected to launch in Q3 2025, and the commencement of dosing for its first gene therapy product, INS1201. These developments position Insmed for substantial growth in the coming years despite associated risks and regulatory uncertainties.
Read more →INSMInsmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation is part of Insmed's efforts to highlight their advancements in therapies for serious diseases. The event will be available for live streaming, indicating the company's commitment to transparency with investors. Insmed is noted for its diverse and innovative portfolio of therapies, as well as its recognition as a top employer in the industry.
Read more →INSMInsmed To Present at December 2024 Investor Conferences Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) has announced its participation in various investor conferences in December 2024. The company focuses on delivering innovative therapies for patients with serious diseases and has a robust pipeline of medicines in advanced stages. Insmed is also noted for its commitment to social responsibility, earning recognition as a top employer in the biopharmaceutical sector. This involvement in conferences underscores its commitment to engaging with investors and sharing progress on its drug development initiatives.
Read more →INSM▲ +5.1%on this newsshared move
Insmed To Present at November 2024 Investor Conferences Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced its participation in upcoming investor conferences, which will be available via live webcasts on their website. The company continues to focus on delivering innovative therapies for serious diseases and has a robust pipeline that includes approved and investigational medicines. Insmed is recognized as a leading employer in the biopharmaceutical sector and is dedicated to patient-centric drug development.
Read more →INSMInsmed Reports Third-Quarter 2024 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Ove
Insmed reported its financial results for Q3 2024, with ARIKAYCE revenues reaching $93.4 million, an 18% increase compared to Q3 2023. The company is on track to submit its New Drug Application for brensocatib in bronchiectasis in Q4 2024, expecting a U.S. launch in mid-2025. Insmed has fully deployed its expanded sales force to raise awareness of the bronchiectasis disease state and support ARIKAYCE's growth. However, the company also faced a significant net loss during the quarter, highlighting ongoing challenges despite revenue growth.
Read more →INSMInsmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated has been named the top employer in Science's 2024 Top Employers Survey, marking its fourth consecutive year at this rank. The survey, which included nearly 6,500 respondents primarily from North America, Europe, and the Asia-Pacific region, recognized Insmed for its innovative leadership and commitment to employee satisfaction. CEO Will Lewis highlighted the company's strong commercial and pipeline programs and the potential of its growing team. Insmed is focused on developing first- and best-in-class therapies for patients with serious diseases.
Read more →INSMInsmed Unites Across Communities Around the World During Third Annual Global Day of Good Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated held its third annual Global Day of Good, involving over 1,000 employees who volunteered across communities in the U.S., Europe, and Japan. This year's event focused on enhancing health, education, and human services, benefiting more than 40 organizations. Volunteers participated in various projects, including supporting pediatric cancer patients and revitalizing community centers. Insmed's commitment to corporate responsibility is reflected in its consistent efforts throughout the year, alongside this major volunteer initiative.
Read more →INSMInsmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated announced it will release its third-quarter 2024 financial results on October 31, 2024. The company's management will host a conference call at 8:00 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can participate via phone or listen to a live webcast on Insmed's website. The company continues to focus on delivering first- and best-in-class therapies for serious diseases.
Read more →INSMNew Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated presented positive subgroup data from the Phase 3 ASPEN study at the CHEST 2024 Annual Meeting. The study demonstrated brensocatib's efficacy in reducing exacerbation rates and slowing lung function decline in patients with bronchiectasis. Positive results support plans for filing a New Drug Application in the U.S. in the fourth quarter of 2024. However, there are risks related to obtaining regulatory approvals and potential inconsistencies in future data.
Read more →INSMInsmed Reports Second-Quarter 2024 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth O
Insmed Incorporated reported its second-quarter 2024 financial results, showcasing a 17% increase in ARIKAYCE revenue, totaling $90.3 million. The company expressed confidence in the upcoming U.S. launch of Brensocatib, with a New Drug Application expected in the fourth quarter of 2024. Significant positive topline data from the Phase 3 ASPEN study was highlighted, which aims to advance treatment options for bronchiectasis patients. Despite these achievements, Insmed continues to face substantial operating losses and high expenses.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated, a biopharmaceutical company, has announced the granting of inducement awards to 97 new employees under NASDAQ Listing Rule 5635(c)(4). Each employee received stock options to purchase an aggregate of 133,130 shares at an exercise price of $75.33 per share. These options include a 10-year term with a four-year vesting schedule, highlighting the company's commitment to incentivizing new talent as it continues to develop therapies for serious and rare diseases. Insmed is also working on an innovative pipeline, including advanced technologies in protein engineering and gene therapy.
Read more →INSMInsmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated has announced its plan to release second-quarter 2024 financial results on August 8, 2024. The company will host a conference call for investors at 8:00 a.m. ET the same day to discuss these results and provide a business update. Insmed is recognized for its commitment to transforming the lives of patients with serious and rare diseases, alongside its ongoing research and development of innovative therapies in various fields.
Read more →INSMAdditional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference -New Graph Depicting 52-Week FEV1 Data Illustrate Significantly
Insmed Incorporated announced additional positive results from the ASPEN study of brensocatib, a Phase 3 trial evaluating its efficacy in bronchiectasis patients. The study showed significantly less decline in lung function and a marked reduction in pulmonary exacerbations compared to placebo. Results are set to be presented at the 7th World Bronchiectasis Conference, highlighting strong support for brensocatib as a potential treatment option. Insmed plans to submit a New Drug Application in late 2024, aiming for a U.S. launch in mid-2025, pending approval.
Read more →INSMInsmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 BRIDGEWATER, N.J.
Insmed Incorporated has announced the redemption of all $225 million of its outstanding 1.75% Convertible Senior Notes due 2025, which will take place on August 9, 2024. The company intends to pay the redemption price in cash, covering the principal amount along with any accrued interest. This move is part of Insmed's broader strategy to manage its debt and enhance its financial position. Additionally, holders of the notes have the opportunity to convert them into shares of common stock prior to the redemption date.
Read more →INSMInsmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024. The event will include a fireside chat that will be webcast live and available for 30 days afterward. Insmed is recognized for its commitment to treating patients with serious and rare diseases, highlighting its innovative therapies and pipelines, including advancements in artificial intelligence-driven protein engineering and gene therapy.
Read more →INSMInsmed Incorporated Commercial Presentation
Insmed Incorporated's commercial presentation on June 4, 2024, included substantial forward-looking statements that highlight significant risks and uncertainties associated with the company's products. These risks include potential delays in obtaining necessary regulatory approvals for brensocatib and TPIP, as well as challenges in maintaining commercial success and market acceptance for ARIKAYCE, their only currently approved product. The company acknowledged the potential for variations in clinical trial data and the impact of external market conditions on their business performance.
Read more →INSM▲ +6.4%on this newsshared move
Insmed to Host Commercial Webinar on June 4, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated (Nasdaq: INSM) announced it will host a commercial webinar on June 4, 2024, to provide insights into the market outlook for its leading drug development programs. The webinar will discuss three key products: ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder. While ARIKAYCE has shown promise in treating Mycobacterium avium complex (MAC) lung disease, the company highlighted various adverse reactions, including hypersensitivity pneumonitis and bronchospasm, that must be considered. Interested parties are encouraged to participate via phone or online streaming.
Read more →INSM▲ +6.4%on this newsshared move
Insmed Announces Pricing of $650 Million Public Offering of Common Stock Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated announced the pricing of a public offering of 12,621,359 shares of common stock at $51.50 per share, aiming to raise approximately $650 million. The proceeds will be allocated towards the research and development of therapies including brensocatib and ARIKAYCE, alongside general corporate purposes. The offering is subject to customary conditions and is expected to close on May 31, 2024. Insmed's initiatives reflect its commitment to advancing treatment options for patients with serious and rare diseases.
Read more →INSM▲ +118.5%on this news· ran to +150% by day 3shared move
Insmed Announces Proposed $500 Million Public Offering of Common Stock BRIDGEWATER, N.J.
Insmed Incorporated has announced its intention to conduct a public offering of $500 million in common stock, with an option for underwriters to purchase an additional 15%. This offering aims to support its mission of providing therapies for patients with serious and rare diseases. The offering is subject to market conditions, and specific details will be outlined in a preliminary prospectus to be filed with the SEC. Insmed has notable products already approved and is advancing a strong pipeline of investigational therapies.
Read more →INSM▲ +118.5%on this news· ran to +150% by day 3shared move
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis -Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Sign
Insmed has announced positive topline results from the Phase 3 ASPEN study evaluating brensocatib in patients with bronchiectasis. Both dosage strengths achieved statistically significant reductions in the frequency of pulmonary exacerbations versus placebo, and multiple secondary endpoints were also met. The company plans to file a New Drug Application with the FDA in late 2024, with an expected U.S. launch in mid-2025. If approved, brensocatib would be the first treatment for bronchiectasis, marking a significant advancement in addressing this condition.
Read more →INSM▲ +118.5%on this news· ran to +150% by day 3shared move
Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated will host a conference call on May 28, 2024, to discuss topline results from its Phase 3 ASPEN study for brensocatib in bronchiectasis patients. The study, which is a global, randomized, double-blind, placebo-controlled trial, aims to evaluate the efficacy, safety, and tolerability of the drug. A press release with detailed results will be issued prior to the call, amplifying the anticipation for the upcoming announcement.
Read more →INSMInsmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session —Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs....
Insmed presented late-breaking results from the Phase 3 ARISE study of ARIKAYCE at the ATS 2024 International Conference, highlighting significant improvements in respiratory symptoms and microbiologic outcomes for patients with MAC lung disease. The study demonstrated better QOL-B Respiratory Domain scores and higher culture conversion rates for ARIKAYCE-treated patients compared to those receiving only a macrolide-based regimen. Notably, no patients developed resistance to the treatment. However, the study was not powered for statistical significance, and the discontinuation rate was higher in the ARIKAYCE group.
Read more →INSMInsmed Reports First-Quarter 2024 Financial Results and Provides Business Update - ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Gr
Insmed Incorporated reported its first-quarter 2024 financial results, revealing a total revenue of $75.5 million for ARIKAYCE, which is a 16% increase from the previous year. The company highlighted positive safety and tolerability data from the Phase 2 PH-ILD study of TPIP, as well as encouraging results from its Phase 2 PAH trial. Despite these positive developments, Insmed continues to face challenges with a significant operating loss and total liabilities surpassing its assets. The company is optimistic about reaching its revenue guidance for ARIKAYCE in 2024, projected to be between $340 million to $360 million.
Read more →INSMInsmed To Present at the BofA Securities Health Care Conference 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated (Nasdaq: INSM) announced that its management team will participate in a fireside chat at the BofA Securities Health Care Conference 2024 on May 14, 2024. The event will take place in Las Vegas, NV, and will be accessible via live webcast. Insmed is known for its mission to improve the lives of patients with serious and rare diseases and is progressing a strong pipeline of investigational therapies. The company's commitment to innovative treatment options is underscored by its ongoing research efforts in various advanced technologies.
Read more →INSMInsmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated announced it will release its first-quarter 2024 financial results on May 9, 2024. A conference call for investors will also take place at 8:00 a.m. ET the same day to discuss these results and provide a business update. Insmed, known for its therapies for serious and rare diseases, is headquartered in Bridgewater, New Jersey, and has a promising pipeline of investigational therapies. This is part of its ongoing mission to improve patient outcomes in challenging health conditions.
Read more →INSMInsmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated announced it will present nine abstracts regarding its respiratory portfolio at the ATS 2024 International Conference. Highlighted presentations include late-breaking data from the ARISE study, which evaluates the effects of ARIKAYCE on microbiological outcomes in patients with Mycobacterium avium complex (MAC) lung disease. Additionally, insights from patient-reported respiratory symptoms will be shared. The conference will take place from May 17-22, 2024, in San Diego, marking a significant opportunity for Insmed to showcase its advancements in therapies for respiratory diseases.
Read more →INSMInsmed To Present at Three March Conferences Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated, a global biopharmaceutical company, announced its participation in three investor conferences scheduled for March. These presentations aim to enhance investor engagement and showcase Insmed's commitment to addressing serious and rare diseases through its innovative therapies. The company has a pipeline targeting unmet medical needs and has previously achieved regulatory approvals in major markets for its first commercial product.
Read more →INSMActress Jane Seymour and Insmed Raise Awareness of Unseenism and Empower People to Speak Up When It Comes to Their Health — New survey reveals the prevalence of Unseenism, which can be described as a social phenomenon where gender and age biases can leave some patients ...
Insmed has partnered with actress Jane Seymour to address the issue of 'Unseenism', where patients, particularly women and older individuals, feel overlooked in healthcare. A survey conducted by Insmed reveals that a significant percentage of patients do not voice their health concerns due to previous dismissals by healthcare providers. The company's 'Speak Up in BE' campaign aims to empower bronchiectasis patients by providing resources and education to help them advocate for their health. The initiative highlights the importance of addressing communication gaps in healthcare to ensure patients feel seen and heard.
Read more →INSMInsmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update -Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out
Insmed Incorporated reported its financial results for Q4 and the full year 2023, highlighting notable growth in ARIKAYCE revenues which exceeded guidance. The company is preparing for the data readout from its Phase 3 ASPEN trial for Brensocatib, scheduled for the latter part of Q2 2024. With a cash reserve of $780 million, Insmed appears well-positioned for future growth despite reporting substantial operating losses during the same period. The firm remains optimistic about potential future catalysts in its clinical pipeline.
Read more →INSMInsmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated announced it will release its fourth-quarter and full-year 2023 financial results on February 22, 2024. The company will hold a conference call for investors on the same date to discuss these results and provide a business update. Interested parties can participate in the call via phone or webcast, and a replay will be available shortly after the call's completion. Insmed continues to focus on addressing serious and rare diseases through its investigational therapies and early-stage research efforts.
Read more →INSMInsmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference -ARIKAYCE (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudit
Insmed Incorporated announced a strong business update at the J.P. Morgan Healthcare Conference, with ARIKAYCE's preliminary unaudited revenues for 2023 exceeding $305 million. The company anticipates continued growth for ARIKAYCE in 2024, projecting revenues between $340 million and $360 million. Additionally, important milestone data for their investigational treatments Brensocatib and TPIP is expected in the second quarter of 2024. However, the financial results remain preliminary and could be subject to adjustment.
Read more →INSMInsmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco. This event will feature a live webcast of the presentation and Q&A session. Insmed focuses on therapies for serious and rare diseases and has a pipeline that includes various investigational treatments. The company has a first-in-disease therapy approved across multiple regions and is developing technologies in protein engineering and gene therapy.
Read more →INSM▲ +5.5%on this news
Insmed To Present at the Nasdaq 49th Investor Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated has announced its participation in the Nasdaq 49th Investor Conference scheduled for December 6, 2023. The presentation will focus on the company's mission to aid patients with serious and rare diseases. Insmed has previously launched a first-in-disease therapy and is advancing several investigational therapies targeting unmet medical needs. The event will be webcast live and archived for 30 days post-event.
Read more →INSMInsmed To Present at Two November Conferences Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated (Nasdaq: INSM) announced its participation in two upcoming investor conferences, which will be available for live webcast. This initiative reflects the company's ongoing commitment to engaging with stakeholders while spotlighting its mission to help patients with serious diseases. Insmed is known for its innovative therapies and a strong pipeline targeting unmet medical needs within rare diseases.
Read more →INSMInsmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated has organized its second annual Global Day of Good, where over 700 employees volunteered in 25 locations across the U.S., Europe, and Japan. This initiative aims to enhance the quality of life in local communities by focusing on health, education, and human services. The event builds on the success of its inaugural year, demonstrating the company's dedication to corporate citizenship and community support. Insmed plans to continue this annual event to further its positive impact worldwide.
Read more →INSMInsmed Reports Third-Quarter 2023 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter o
Insmed reported its third-quarter 2023 financial results, highlighting robust revenue generation from ARIKAYCE, marking the highest quarterly sales since its launch. The company confirmed its revenue guidance for the full year, expecting between $295 million and $305 million. Furthermore, Insmed shared positive data from its TPIP and Brensocatib trials, enhancing its mid- to late-stage pipeline prospects. Despite these optimistic trends, Insmed faced a notable net loss, primarily due to rising operating expenses.
Read more →INSMInsmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated (Nasdaq: INSM) has been recognized as the top employer in the biopharma sector, topping Science's 2023 Top Employers Survey for the third year in a row. This accolade was based on feedback from over 6,800 employees in the biotechnology and pharmaceutical industries. The survey highlighted Insmed's strong culture, innovative leadership, and commitment to employee well-being. Insmed continues to advance its mission of transforming the lives of patients facing rare and serious diseases, while also fostering a dynamic workplace culture.
Read more →INSMInsmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug...
Insmed Incorporated has announced a collaboration with Google Cloud to improve drug discovery, development, and commercialization using generative AI. The partnership focuses on several key areas, with one to three projects planned for completion within the next 18 months. This collaboration aims to reduce time and costs in bringing therapies to patients with serious conditions. Although the potential for significant advancements exists, there are inherent risks and uncertainties in realizing these ambitious goals in the life sciences sector.
Read more →INSMInsmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated announced they will release their third-quarter 2023 financial results on October 26, 2023. A conference call for investors will take place at 8:30 a.m. ET to discuss these results and provide a business update. Participants can join via phone or listen to a live webcast. Insmed continues to advance its therapeutic pipeline focused on serious and rare diseases, including their first-in-disease therapy approved in several key markets.
Read more →INSMInsmed To Present at Chardan's 7th Annual Genetic Medicines Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated has announced its participation in Chardan's 7th Annual Genetic Medicines Conference, where management will present during a fireside chat on October 3, 2023. The event aims to highlight Insmed's efforts to address serious and rare diseases through innovative therapies. The presentation will be available via a live webcast, which will be archived for 30 days. Insmed continues to advance its pipeline, including therapies for neutrophil-mediated inflammatory diseases and rare pulmonary disorders.
Read more →INSMInsmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated has announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference scheduled for September 11, 2023. The company's management will engage in a fireside chat that will be webcast live. Insmed is recognized for its commitment to developing therapies for serious and rare diseases, boasting a first commercial product approved in major markets and a promising pipeline of investigational therapies. The event aims to provide insights into Insmed's strategies and ongoing projects.
Read more →INSM▲ +16.5%on this newsshared move
INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC - QOL-B Respiratory Domain Shown to Work Effectivel
Insmed announced positive topline results from its Phase 3 ARISE study of ARIKAYCE in patients with MAC lung disease. The study demonstrated that the Quality of Life - Bronchiectasis (QOL-B) respiratory domain effectively serves as a patient-reported outcome tool. ARIKAYCE-treated patients exhibited higher culture conversion rates and significant improvement in respiratory scores compared to those receiving a placebo. Insmed plans to propose QOL-B as the primary endpoint for its upcoming ENCORE study and aims for accelerated filing with global regulators based on ARISE results.
Read more →INSMInsmed Reports Second-Quarter 2023 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter
Insmed Incorporated reported its financial results for the second quarter of 2023, highlighting a record revenue of $77.2 million for ARIKAYCE, marking strong growth of 18% year-over-year. The company has raised its full-year revenue guidance for ARIKAYCE to between $295 million and $305 million, bolstered by positive sales momentum in the U.S. and Japan. Additionally, Insmed indicated that key data readouts from its clinical trials, including the ARISE study and the Phase 3 ASPEN trial of Brensocatib, are forthcoming. Nonetheless, the company reported a significant net loss of $244.8 million and substantial operating expenses, primarily in research and development.
Read more →INSMInsmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated announced it will release its second-quarter 2023 financial results on August 3, 2023. Management will host a conference call for investors at 8:30 a.m. ET to discuss these results and provide a business update. Shareholders can participate in the call by phone or via a live web broadcast on the company's website. Insmed is known for its innovative therapies in serious and rare diseases, indicating a focus on advancing healthcare solutions.
Read more →INSMInsmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated has announced its participation in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference scheduled for June 14, 2023. The event aims to showcase the company's mission of transforming the lives of patients dealing with serious and rare diseases. Insmed's first commercial product has been approved in major markets for a chronic lung disease, and the company continues to develop therapies for unmet medical needs. The chat will be accessible via a live webcast from the company's investor relations website.
Read more →INSMInsmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference —Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2...
Insmed Incorporated presented significant findings at the American Thoracic Society 2023 International Conference, including promising data on brensocatib, which has shown to reduce exacerbations in patients with non-cystic fibrosis bronchiectasis irrespective of disease severity. Additional findings revealed that early diagnosis of nontuberculous mycobacterial lung disease may lead to lower hospitalization rates for patients with chronic obstructive pulmonary disease. The data stems from Phase 2 trials and real-world cohort studies, emphasizing Insmed’s commitment to addressing rare and serious diseases.
Read more →INSMInsmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More" -Early-Stage Research Pillar Anticipat
Insmed Incorporated recently unveiled its early-stage research advancements at an investor and analyst event, focusing on innovative gene therapies and other platforms. The company plans to initiate a clinical trial for Duchenne Muscular Dystrophy (DMD) in 2023 and aims to submit at least six investigational new drug applications by the end of 2025. A notable $500,000 investment from CureDuchenne Ventures will aid the development of a targeted gene therapy for DMD. Insmed is also exploring novel manufacturing techniques and targeted delivery systems to enhance the safety and efficacy of its therapies.
Read more →INSMInsmed Reports First Quarter 2023 Financial Results and Provides Business Update -Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second
Insmed Incorporated reported its financial results for the first quarter of 2023, highlighting successful enrollment completion in the Phase 3 ASPEN trial for Brensocatib. The company also reported a 23% year-over-year increase in ARIKAYCE revenue, amounting to $65.2 million. Despite these positives, Insmed experienced a net loss of $159.8 million, an increase from the previous year, influenced by high operating expenses. Looking ahead, the company reaffirmed its revenue guidance for ARIKAYCE in 2023 and is set to provide updates on early-stage research efforts.
Read more →INSMInsmed to Host Investor and Analyst Event on May 8, 2023 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated has announced an upcoming investor and analyst event scheduled for May 8, 2023, in New York, focusing on their research initiatives. The event, titled "The Future of Rare at Insmed," will feature discussions on its early-stage programs and the potential to submit at least six new investigational drug applications by 2025. The company's commitment to addressing serious and rare diseases will also be highlighted. A live webcast of the event will be available on Insmed's website.
Read more →INSMInsmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated announced it will release its financial results for the first quarter of 2023 on May 4, 2023. The company will host a conference call with investors at 8:30 a.m. ET to discuss the results and provide a business update. Insmed continues its mission to transform the lives of patients with serious and rare diseases and has a robust pipeline targeting unmet medical needs. The company is also known for its first-in-disease therapy approved in multiple regions.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated announced the granting of inducement awards to 24 new employees as part of its hiring strategy, compliant with NASDAQ Listing Rule 5635(c)(4). The inducement grants include options to purchase a total of 182,880 shares of common stock at an exercise price reflecting the latest trading price. Options have a 10-year term with a progressive vesting schedule, aimed at retaining talent within the company. Insmed continues to focus on developing therapies for serious diseases, reinforcing its commitment to innovation and patient care.
Read more →INSMInsmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed has successfully completed the enrollment of over 1,700 adult patients in the Phase 3 ASPEN study of brensocatib, aimed at treating bronchiectasis. This global, randomized trial is crucial in assessing the efficacy and safety of brensocatib, with topline data set to be reported in the second quarter of 2024. The ASPEN study is recognized as the largest single Phase 3 trial ever conducted for bronchiectasis, highlighting the significant unmet need for effective treatments in this area. The study continues to progress with ongoing enrollment of adolescent patients.
Read more →INSMInsmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated will present new clinical, pre-clinical, and real-world data on serious and rare lung diseases at the ATS 2023 International Conference. The company will share insights from studies on ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP). These presentations aim to shed light on treatment outcomes and address the challenges faced by patients and healthcare providers. While ARIKAYCE shows promise in alleviating certain lung diseases, it is also linked to significant respiratory side effects, which are important considerations for its continued use.
Read more →INSMInsmed To Present at Two March Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated, a biopharmaceutical company based in Bridgewater, NJ, announced its upcoming presentations at two investor conferences. The events will be available via live webcast and archived for later access. Insmed is known for its commitment to developing therapies for rare and serious diseases, with a focus on unmet medical needs. Its first commercial product is an approved treatment for a chronic lung disease, indicating its active role in the biopharmaceutical space.
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout
Insmed has announced its fourth quarter and full year 2022 financial results, highlighting the completion of patient screening in the Phase 3 ASPEN trial of Brensocatib for bronchiectasis. The company anticipates reporting topline data in Q2 2024, which is seen as a crucial step forward. Additionally, Insmed reported a significant revenue increase for its product ARIKAYCE. However, the company still faces challenges, such as ongoing risks related to investigational drugs and side effects associated with ARIKAYCE.
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated (Nasdaq: INSM) has announced that it will release its fourth quarter and full year 2022 financial results on February 23, 2023, followed by a conference call for investors. The call, starting at 8:30 a.m. ET, will include a discussion of the financial results and a business update. Insmed is noted for its mission to transform the lives of patients with serious and rare diseases and has a first-in-disease therapy approved in multiple regions. The company is also advancing several investigational therapies.
Read more →INSMInsmed To Present at the SVB Securities Global Biopharma Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Incorporated, a biopharmaceutical company focused on serious and rare diseases, announced its participation in the SVB Securities Global Biopharma Conference on February 14, 2023. The management will engage in a fireside chat that will be accessible via webcast. Insmed is recognized for its first-in-disease therapy approved in the US, Europe, and Japan, and is advancing a pipeline aimed at addressing unmet medical needs.
Read more →INSM▼ -6.3%on this news
Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference —Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment...
Insmed Incorporated provided a business update during the 41st Annual J.P. Morgan Healthcare Conference, highlighting positive topline data from its Phase 2 PK/PD study of brensocatib for cystic fibrosis. The company anticipates a 30% growth in ARIKAYCE revenues for 2022, with projected global revenues between $285 million and $300 million. However, there are significant safety concerns with ARIKAYCE, including risks of serious respiratory adverse reactions and treatment discontinuation rates. Insmed detailed its near-term strategic priorities, focusing on ARIKAYCE, brensocatib, and early-stage research initiatives.
Read more →INSMInsmed To Present at the 41st Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Insmed Incorporated announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2023. The presentation will be webcast live, providing access to a broader audience. Insmed focuses on developing therapies for serious and rare diseases, with its first commercial product already approved in key regions. The company is also advancing a promising pipeline targeting unmet medical needs.
Read more →INSMInsmed To Present at the Nasdaq 47th Investor Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47 th Investor Conf
Read more →INSMInsmed To Present at Three November Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Nov. 1, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferen
Read more →INSMInsmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
--Insmed Leads Science Top Employers List for Second Year in a Row -- BRIDGEWATER, N.J. , Oct. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today a
Read more →INSMInsmed Reports Third Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of
Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch-
Read more →INSM▼ -14.7%on this news
Insmed Announces Strategic Financings Totaling $775 Million -$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing- -$275 million underwritten offering of commo
Insmed Announces Strategic Financings Totaling $775 Million -$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing- -$275 million underwritten offering of common stock- -Financings increase cash and cash equivalents a
Read more →INSMInsmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results
Read more →INSMInsmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
— More than 500 Insmed employees volunteer across 13 sites in the U.S., Europe , and Japan — BRIDGEWATER, N.J. , Oct. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and
Read more →INSMInsmed To Present at Two September Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
Read more →INSM▲ +15.2%on this news· ran to +28% by day 1shared move
Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue o
Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launc
Read more →INSMInsmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2022 financial results
Read more →INSMInsmed Names Drayton Wise Chief Commercial Officer BRIDGEWATER, N.J.
Insmed Names Drayton Wise Chief Commercial Officer BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointmen
Read more →INSM▲ +9.1%on this news
Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE ® (amikacin liposome inhalation suspension) Initiation in Real-World Settings— —Post-Hoc Analysis of Phase 2 WILLOW Study in
Read more →INSM▲ +9.1%on this news
Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, NJ , , May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wai
Read more →INSMInsmed Reports First Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million- -Seven Clinical Trials Underway; Enrollmen
Read more →INSM▼ -5.6%on this news
Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 21, 2022 /PRNewswire/ -- Insmed Incorporated ( Nasdaq : INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial resul
Read more →INSMInsmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE ® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session-- --Analysis of Phase 2 WILLOW Study Evaluating the Benefit-Risk Profile of Brensocatib
Read more →INSMInsmed To Present at the Cowen 42nd Annual Health Care Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Cowen 42 nd Annual Health
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $
Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least
Read more →INSMInsmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the SVB Leerink Virtual 11 th
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Jan. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2021 fin
Read more →INSMThis presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are s
This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a numbe
Read more →INSMInsmed To Present at the 40th Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Jan. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 40 th Annual J.P. M
Read more →INSMInsmed To Participate in Three November Conferences Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual
Read more →INSM▲ +12.1%on this news
Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has ranked as the top company to work for in Science '
Read more →INSM▲ +12.1%on this news
Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan- -Continuing to
Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in -Continuing to Advance ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalat
Read more →INSM▼ -6.7%on this news
Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2021 financial results
Read more →INSMInsmed To Participate in Five September Conferences Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual
Read more →INSMInsmed Reports Second Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories- -Continuing to Progress A
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories- -Continuing to Progress ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation
Read more →INSMInsmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results
Read more →INSMInsmed To Present at Two June Conferences Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual inve
Read more →INSMInsmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across
Read more →INSMInsmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes BRIDGEWATER, NJ
Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes BRIDGEWATER, NJ, May 13, 2021 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM) announced today the closi
Read more →INSMInsmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock...
BRIDGEWATER, N.J. , May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the public of $25.00 per share before deducting unde
Read more →INSMInsmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 BRIDGEWATER, NJ
Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 BRIDGEWATER, NJ, May 10, 2021 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "
Read more →INSMInsmed Reports First Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficie
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug -ARIKAYCE
Read more →INSMInsmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 22, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2021 financial results
Read more →INSMARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) ha
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands- -Frontline Clinica
Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands- -Frontline Clinical Trial Program of ARIKAYCE(R) (amikacin liposome inhalat
Read more →INSMInsmed to Present at Two March Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual inve
Read more →INSMInsmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) -TPIP Generally Safe and Well Tolerated in Healthy Volunteers- -TPIP Showed Substantially Lower C max and Longer Half-
Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) -TPIP Generally Safe and Well Tolerated in Healthy Volunteers- -TPIP Showed Substantially Lower Cmax and Longer Half-Life than Currently Available Inhaled Treprostinil Therapy-
Read more →INSMInsmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy vol
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 fin
Read more →INSMPromising Therapies Inspired by Urgent Unmet Patient Needs Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements, as
Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy Systemic disorders: sarcoidosis, pulmonary histiocytosis: lymphangioleiomyomatosis Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders Others: tumoral obstruct
Read more →INSMInsmed to Present at the 39th Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 39 th Annual J.P. M
Read more →INSMInsmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Jan. 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient was dosed in late December, 2020, in the
Read more →INSMInsmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Dec. 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient has been dosed in the Phase 3 ASPEN stud
Read more →INSMInsmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3 rd
Read more →INSMInsmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority
Read more →INSMInsmed to Present at Two November Conferences Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Nov. 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor
Read more →INSMInsmed Reports Third Quarter 2020 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020- -Marketing Authorization for ARI
Reports Third Quarter 2020 Financial Results and Provides Business Update (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020- Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion Granted in European Union- New Drug Appli
Read more →INSMEuropean Commission Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options - ARIKA
Commission Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options ARIKAYCE is the First and Only Therapy Approved in Both the European Unio
Read more →INSMLa Commission européenne accorde une autorisation de mise sur le marché pour le nébuliseur ARIKAYCE® Liposomal 590 mg, pour le traitement des infections pulmonaires à MNT chez les patients adultes qui ne présentent pas de mucoviscidose et dont les options de traitement sont limitées Insmed Incorporated (Nasdaq: INSM), une entreprise biopharmaceutique mondiale dont la mission est de transformer la vie des patients atteints de...
— ARIKAYCE est le premier et le seul traitement approuvé dans l'Union européenne (UE) et aux États-Unis pour cette indication difficile à traiter — — Le lancement est prévu pour commencer en Allemagne suivi du Royaume-Uni puis dans d'autres autres pays de l'UE par la suite — BR
Read more →INSMLa Comisión Europea concede la autorización de marketing para ARIKAYCE® Liposomal 590 mg - La Comisión Europea concede la autorización de marketing para ARIKAYCE® Liposomal 590 mg dispersión por nebulizador para el tratamiento de las...
- La Comisión Europea concede la autorización de marketing para ARIKAYCE® Liposomal 590 mg dispersión por nebulizador para el tratamiento de las infecciones de pulmón NTM causadas por MAC en pacientes adultos no CF con opciones de tratamiento limitadas — ARIKAYCE es la primera y
Read more →INSMLa Commissione europea autorizza la commercializzazione di ALIS (Amikacin Liposome Inhalation Suspension) dispersione per aerosol per il trattamento di infezioni polmonari NTM causate da MAC in pazienti adulti non FC con opzioni di trattamento limitate Insmed Incorporated (Nasdaq: INSM), società biofarmaceutica globale la cui missione è trasformare la vita di pazienti affetti da malattie gravi e...
— Il lancio del prodotto inizierà in Germania , poi nel Regno Unito; a seguire altri paesi dell'UE — BRIDGEWATER, New Jersey , 28 ottobre 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), società biofarmaceutica globale la cui missione è trasformare la vita di pazienti a
Read more →INSMInsmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BRIDGEWATER, N.J., Oct. 2, 2020 /PRNewswire/ – Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the...
BRIDGEWATER, N.J. , Oct. 2, 2020 /PRNewswire/ – Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to nine new employees. In acco
Read more →INSMInsmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day - Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned f
Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day - Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 - - Expects to initiate registrational Phase 3
Read more →INSMInsmed to Host R&D Day on September 30, 2020 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Sept. 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020
Read more →INSMInsmed to Present at Three September Conferences Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor
Read more →INSMNew England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Sept. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocati
Read more →INSMInsmed Reports Second Quarter 2020 Financial Results and Provides Business Update -ARIKAYCE (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020- -ARIKAYCE Included in New Inte
Second Quarter 2020 Financial Results and Provides Business Update (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020- Included in New International Treatment Guidelines for NTM Lung Disease; Positive CHMP Opinion in European Union
Read more →INSMInsmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results
Read more →INSMInsmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , July 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP)
Read more →INSMFINAL Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options -If Approved, ARIKAY
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options -If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for T
Read more →INSMNew NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE ® (amikacin liposome inhalation suspension) has b
Read more →INSMPositive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocati
Read more →INSMInsmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , June 8, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted br
Read more →INSMInsmed to Present at Two June Conferences Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , May 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis , Chairman and Chief Executive Officer of Insme
Read more →INSMInsmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , May 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new data from the Phase 2 WILLOW study of brensocatib (for
Read more →INSMInsmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares BRIDGEWATER, NJ
Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares BRIDGEWATER, NJ, May 7, 2020 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced public off
Read more →INSMInsmed Announces Pricing of Public Offering of Common Stock Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock...
BRIDGEWATER, N.J. , May 5, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share. The gross proceeds to Insmed from the
Read more →INSMInsmed Announces Proposed Public Offering of Common Stock BRIDGEWATER, NJ
Insmed Announces Proposed Public Offering BRIDGEWATER, NJ, May 4, 2020 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the un
Read more →INSMInsmed Reports First Quarter 2020 Financial Results and Provides Business Update - Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development i
Insmed Reports First Quarter 2020 Financial Results and Provides Business Update BRIDGEWATER, N.J., April 30, 2020 /PRNewswire/ - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseas
Read more →INSMBrensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 23, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will provide funding and clinical drug supply for the
Read more →INSMInsmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2020 financial results
Read more →INSMInsmed Appoints Carol A. Schafer to its Board of Directors BRIDGEWATER, N.J.
Insmed Appoints Carol A. Schafer to its Board of Directors BRIDGEWATER, N.J., April 2, 2020 /PRNewswire/ - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the
Read more →INSMInsmed Provides Business Update Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , March 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a general business update. Submission of New Drug Application
Read more →INSMInsmed Provides Business Update - Company Submits New Drug Application in Japan for ARIKAYCE (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC - - AstraZeneca Exe
Insmed Provides Business Update - Company Submits New Drug Application in Japan for ARIKAYCE (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease - AstraZeneca Exercises Exclusive Option to Develop INS1007 in Chronic Obstructive Pulmon
Read more →INSMInsmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , March 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced publication of results from a survey of patients with refracto
Read more →INSMInsmed to Present at the Cowen and Company 40th Annual Health Care Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insme
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 25, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended De
Read more →INSMInvestor Presentation February 2020 Not for promotional use This presentation contains forward - looking statements that involve substantial risks and uncertainties. "Forward - looking stateme nts," as that term is defin
Investor Presentation February 2020 Not for promotional use This presentation contains forward - looking statements that involve substantial risks and uncertainties. "Forward - looking stateme nts," as that term is defined in the Private Securities Litigation Reform Act of 1995,
Read more →INSMInsmed Reports Fourth Quarter and Full
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year -Company Provides Full-Year 2020 ARIKAYCE Revenue Gu
Read more →INSMInsmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Feb. 19, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insme
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Feb. 10, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and year-end financial
Read more →INSMInsmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis - Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Pl
Read more →INSMInsmed Appoints Sara Bonstein as Chief Financial Officer Bridgewater, N.J.
Insmed Appoints Sara Bonstein as Chief Bridgewater, N.J., January 30, 2020 /PRNewswire/ - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Sa
Read more →INSMInvestor Presentation January 2020 Not for promotional use This presentation contains forward - looking statements that involve substantial risks and uncertainties. "Forward - looking stateme nts," as that term is define
Investor Presentation January 2020 Not for promotional use This presentation contains forward - looking statements that involve substantial risks and uncertainties. "Forward - looking stateme nts," as that term is defined in the Private Securities Litigation Reform Act of 1995,
Read more →INSMInsmed to Present at the 38th Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Jan. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed
Read more →INSMInsmed to Present at Two December Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Nov. 26, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor confere
Read more →INSMInsmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer -Drayton Wise named Senior Vice President, Head of U.S. Bridgewater, N.J.
Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer -Drayton Wise named Senior Vice President, Bridgewater, N.J., November 14, 2019 /PRNewswire/ - Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical compan
Read more →INSMInsmed Reports Third Quarter 2019 Financial Results and Provides Business Update Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Oct. 30, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 201
Read more →INSMInsmed Reports Third Quarter 2019 Financial
Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019- -Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $133 Million to $138 Million- -
Read more →INSMInsmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Oct. 23, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2019 financial results
Read more →INSMInsmed to Present at Two September Conferences Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , Sept. 3, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor confere
Read more →INSMInsmed Reports Second Quarter 2019 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019 Marketing Authoriza
Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019 Marketing Authorization Application for ARIKAYCE Submitted and Validated by E
Read more →INSMInsmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , July 25, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2019 financial results
Read more →INSMInsmed Announces Closing of Public Offering of Common Stock Insmed Incorporated (Nasdaq: INSM) today announced the closing on June 25, 2019 of the issuance of an additional 1,442,307 shares of common stock...
BRIDGEWATER, N.J. , June 26, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ) today announced the closing on June 25, 2019 of the issuance of an additional 1,442,307 shares of common stock pursuant to the full exercise of the underwriter's overallotment option related to
Read more →INSMInsmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , June 6, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed
Read more →INSMInsmed Announces Closing of Public Offering of Common Stock BRIDGEWATER, NJ
Insmed Announces Closing of Public Offering of Common Stock BRIDGEWATER, NJ, May 24, 2019 /PRNewswire/ Insmed Incorporated (Nasdaq: INSM) today announced the closing of the previously announced public offering of its common stock. Insmed issued and sold in the public offering 9,
Read more →INSMInsmed Announces Pricing of Public Offering of Common Stock Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock,...
BRIDGEWATER, N.J. , May 21, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share before underwriting discounts and co
Read more →INSMNew Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , May 20, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE ® (
Read more →INSMInsmed Reports First Quarter 2019 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 Company Raises Full-Y
Insmed Reports First Quarter 2019 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $90 Million
Read more →INSMInsmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 30, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results
Read more →INSMInsmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 9, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued p
Read more →INSMInsmed Provides Update on ARIKAYCE (amikacin liposome inhalation suspension) U.S. Launch ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019 BRIDGEWATER, N.J.
Insmed Provides Update on ARIKAYCE (amikacin liposome inhalation suspension) U.S. Launch ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019 BRIDGEWATER, N.J., April 8, 2019 /PR Newswire/ Insmed Incorporated (Nasdaq:INSM), a glo
Read more →INSMInsmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE ® (amikacin liposome inhala
Read more →INSMInsmed to Present at the H.C. Wainwright Global Life Sciences Conference Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insme
Read more →INSMFINAL Insmed Announces Management Changes BRIDGEWATER, N.J.
BRIDGEWATER, N.J., March 27, 2019 /PR Newswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi, Chief Financial Officer, will be leaving the c
Read more →INSMInsmed Announces Management Changes Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
BRIDGEWATER, N.J. , March 27, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi , Chief Financial Officer, will be leaving
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Ye
Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update ARIKAYCE (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018 Company Provides Full-Year 2019 ARIKAYCE Revenue G
Read more →INSMInsmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
BRIDGEWATER, N.J. , Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insme
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
BRIDGEWATER, N.J. , Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its fourth quarter and year-end financial results on Friday, F
Read more →INSMInsmed Provides Update on ARIKAYCE (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019 ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the
Insmed Provides Update on ARIKAYCE (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019 ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018 More Than 500 Patients Have Initia
Read more →INSMInsmed Announces Changes to its Board of Directors
Insmed Incorporated has announced significant changes to its board of directors, including the appointment of Elizabeth McKee Anderson as a new director. Donald Hayden, Jr. stepped down as chairman after 13 years, with CEO Will Lewis taking over the role. David Brennan has been elected as the lead independent director. These changes aim to strengthen the board's capabilities as Insmed advances its commercial strategy.
Read more →INSMInsmed to Present at Three November Conferences
Insmed Incorporated has announced its participation in three investor conferences scheduled for November. The presentations will be accessible via live webcast and archived for 90 days. Insmed is dedicated to transforming the lives of patients with serious and rare diseases, with a focus on its commercial product ARIKAYCE and its clinical pipeline.
Read more →INSMInsmed Reports Third Quarter 2018 Financial Results and Provides Business Update
Insmed Incorporated announced its third quarter 2018 financial results, highlighting the FDA's accelerated approval of ARIKAYCE for treating MAC lung disease. The company has begun its commercial launch and is focused on expanding its market presence. Despite a net loss reported for the quarter, Insmed maintains a strong cash position, supporting its growth initiatives.
Read more →INSMInsmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018
Insmed Incorporated has announced the release of its third quarter 2018 financial results, scheduled for October 30, 2018. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested parties can participate via phone or listen to a live webcast on Insmed's website.
Read more →INSMInsmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)
Insmed Incorporated presented new data at IDWeek 2018 and the CHEST Annual Meeting, enhancing the understanding of Mycobacterium avium complex (MAC) lung disease and the treatment with ARIKAYCE. The company highlighted the serious nature of MAC lung disease, which has high mortality rates, and emphasized the recent FDA approval of ARIKAYCE as a vital treatment option for patients with limited alternatives. Ongoing clinical trials aim to provide further insights into treatment efficacy.
Read more →INSMInsmed Extends Patent Protection in Japan to 2033
Insmed Incorporated announced the issuance of a new patent for its amikacin liposome inhalation suspension (ALIS) by the Japanese Patent Office, extending its patent protection until May 2033. This patent is significant for treating nontuberculous mycobacterial infections, aligning with Insmed's strategy to launch ALIS in Japan, where NTM lung disease is prevalent. The company aims to enhance its intellectual property protection further.
Read more →INSMInsmed to Present at Two October Conferences
BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences: The Canto
Read more →INSMInsmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
Insmed has received FDA accelerated approval for ARIKAYCE, the first therapy specifically indicated for Mycobacterium avium complex (MAC) lung disease in adults with limited treatment options. This approval is based on positive results from the Phase 3 CONVERT study, which demonstrated improved sputum culture conversion rates. ARIKAYCE will be available in select specialty pharmacies, and Insmed has launched a support program for patients.
Read more →INSMPivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine
Insmed announced the publication of pivotal Phase 3 CONVERT study data for ALIS, demonstrating a significant culture conversion rate in patients with treatment-refractory NTM lung disease caused by MAC. The study found that 29.0% of patients receiving ALIS plus guideline-based therapy achieved culture conversion by Month 6, compared to 8.9% on guideline-based therapy alone. ALIS is currently under FDA Priority Review, with the potential to be the first approved therapy for this condition.
Read more →INSMInsmed Reports Second Quarter 2018 Financial Results and Provides Business Update PDUFA (Prescription Drug User Fee Act ) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for
Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018 Actively Preparing for Potential Product Launch in Early Q4 2018 B
Read more →INSMInsmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018
BRIDGEWATER, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on Thursday, August
Read more →INSMInsmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
BRIDGEWATER, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Division of Antimicrobial Products of the U.S. Food and Drug Administrati
Read more →INSMInsmed to Present at Three June Conferences
BRIDGEWATER, N.J., June 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will present at the following investor conferences: The Nasdaq 38
Read more →INSMInsmed Announces Presentations at the American Thoracic Society 2018 International Conference
Data support the benefit of treating patients with a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy (GBT) for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) Improvements in S
Read more →INSMInsmed Appoints Leo Lee to its Board of Directors Pharmaceutical executive brings insights from more than two decades of pharmaceutical experience in Japan to Board BRIDGEWATER, N.J.
Insmed Appoints Leo Lee to its Board of Directors Pharmaceutical executive brings insights from more than two decades of pharmaceutical experience in Japan to Board BRIDGEWATER, N.J., May 17, 2018 (GLOBE NEWSWIRE) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical co
Read more →INSMInsmed Appoints Leo Lee to its Board of Directors
BRIDGEWATER, N.J., May 17, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Leo Lee to its Board of Directors. Mr. Lee has more than 21 year
Read more →INSMInsmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC PDUFA Action Date Set for
Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC PDUFA Action Date Set for September 28, 2018 BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focu
Read more →INSMInsmed Reports First Quarter 2018 Financial Results and Provides Business Update
Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority review Actively preparing for potential product launch of ALIS in 4Q 2018 BRIDGEWATER, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nas
Read more →INSMInsmed to Present at the Deutsche Bank 43rd Annual Health Care Conference
BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at t
Read more →INSMInsmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018
BRIDGEWATER, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on Wednesday, May 2
Read more →INSMInsmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP) BRIDGEWATER, N.J.
Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP) BRIDGEWATER, N.J., March 29, 2018 (GLOBE NEWSWIRE) Insmed Incorporated (Nasd
Read more →INSMInsmed to Present at the Cowen and Company 38th Annual Health Care Conference
BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that a member of the management team will present at the Cowen and Company 38th A
Read more →INSMInsmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update On track to file NDA before the end of March and anticipate a priority review Extended amikacin liposome inhalation suspensi
Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update On track to file NDA before the end of March and anticipate a priority review Extended amikacin liposome inhalation suspension (ALIS) intellectual property protection to 2035 with is
Read more →INSMInsmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent
BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent Numb
Read more →INSMInsmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018
BRIDGEWATER, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its fourth quarter and year-end financial results on Friday,
Read more →INSMINVESTOR PRESENTATION Safe Harbor Statement 2 This presentation contains forward looking statements. Forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, are statem
INVESTOR PRESENTATION Safe Harbor Statement 2 This presentation contains forward looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number o
Read more →INSMInsmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference
BRIDGEWATER, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at
Read more →INSMInsmed Announces Closing of Public Offering BRIDGEWATER, NJ
Insmed Announces Closing of Public Offering BRIDGEWATER, NJ, January 26, 2018 Insmed Incorporated (Nasdaq: INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025. Insmed issued and sold in the public offering
Read more →INSMInsmed Announces Closing of Public Offering
BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025. Insmed issued and sold in the public offering $450 million aggregate pri
Read more →INSMInsmed Announces Pricing of Public Offering of Convertible Senior Notes
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced its registered underwritten public offering of $400 million aggregate principal amount of its 1.75% convertible senior notes due 2025. Net proceeds from the offe
Read more →INSMInsmed Announces Proposed Public Offering of Convertible Senior Notes BRIDGEWATER, NJ
Insmed Announces Proposed Public Offering of Convertible Senior Notes BRIDGEWATER, NJ, January 22, 2018 Insmed Incorporated (Nasdaq: INSM) announced today that it has commenced an underwritten public offering of $300 million aggregate principal amount of convertible senior notes
Read more →INSMInsmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commerci
Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations Interim results from INS-312 show that 28%
Read more →INSMInsmed to Present at the Nasdaq 37th Annual Investor Conference
BRIDGEWATER, N.J., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at
Read more →INSMInsmed to Present at Two November Conferences
BRIDGEWATER, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed will present at t
Read more →INSMInsmed Reports Third Quarter 2017 Financial Results and Provides Business Update During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalat
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused b
Read more →INSMInsmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017
BRIDGEWATER, N.J., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2017 financial results on Thursday, Novembe
Read more →INSMInsmed to Present at Two September Investor Conferences
BRIDGEWATER, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at
Read more →INSMInsmed Announces Pricing of Public Offering of Common Stock
BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in a registered underwritten public offering at a price of $28.50 per share before underwriting discounts an
Read more →INSMInsmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused b
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) Study met primary endpo
Read more →INSMInsmed Reports Second Quarter 2017 Financial Results and Provides Business Update On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non
Read more →INSMInsmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its second quarter 2017 financial results on Thursday, August
Read more →INSMWelcome & Opening Remarks Will Lewis, President and Chief Executive Officer NTM and the Unmet Medical Need Dr. Kevin L. Winthrop, M.D., M.P.H. Professor, School of Public Health, Associate Professor, Departments of Infec
Welcome & Opening Remarks Will Lewis, President and Chief Executive Officer NTM and the Unmet Medical Need Dr. Kevin L. Winthrop, M.D., M.P.H. Professor, School of Public Health, Associate Professor, Departments of Infectious Diseases and Ophthalmology, Oregon Health & Science Un
Read more →INSMInsmed to Host Analyst and Investor Day on July 19, 2017
BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that it will host an Analyst and Investor Day on Wednesday, July 19, 2017. The eve
Read more →INSMInsmed to Present at the JMP Securities Life Sciences Conference
BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at
Read more →INSMInsmed Announces Key Additions to its Executive Management Team Paolo Tombesi named as Chief Financial Officer Paul Streck, M.D., appointed as Chief Medical Officer Eugene Sullivan, M.D., assumes role of Chief Product St
Insmed Announces Key Additions to its Executive Management Team Paolo Tombesi named as Chief Financial Officer Paul Streck, M.D., appointed as Chief Medical Officer Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer Bridgewater, N.J., May 15, 2017 (GLOBE NE
Read more →INSMInsmed Reports First Quarter 2017 Financial Results and Provides Business Update Advancing Toward Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30
Insmed Reports First Quarter 2017 Financial Results and Provides Business Update Advancing Toward Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30 AM ET BRIDGEWATER, N.J., May 3, 2017 (GLOBE NEWSWIRE) Insmed Incorporated (Nasdaq:INSM), a global biop
Read more →INSMInsmed to Present at the Deutsche Bank 42nd Annual Health Care Conference
BRIDGEWATER, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at
Read more →INSMInsmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017
BRIDGEWATER, N.J., April 26, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2017 financial results on Wednesday, May 3
Read more →INSMInsmed to Present at the Cowen and Company 37th Annual Health Care Conference
BRIDGEWATER, N.J., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at
Read more →INSMInsmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update On Track to Report Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30
Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update On Track to Report Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30 AM ET BRIDGEWATER, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) Insmed Incorporated (Nasdaq:INSM), a global
Read more →INSMInsmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017
BRIDGEWATER, N.J., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its fourth quarter and year-end financial results on Thursday
Read more →INSMInsmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent
BRIDGEWATER, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent Numb
Read more →INSMInsmed to Present at the 35th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the 35th Annual J.P. Morgan Healthcare Confere
Read more →INSMInsmed to Participate at November Investor Conferences
BRIDGEWATER, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking plac
Read more →INSMInsmed Reports Third Quarter 2016 Financial Results and Provides Business Update Enrollment objective achieved in phase 3 CONVERT study Conference call today at 8:30
Insmed Reports Third Quarter 2016 Financial Results and Provides Business Update Enrollment objective achieved in phase 3 CONVERT study Conference call today at 8:30 AM ET BRIDGEWATER, N.J., November 3, 2016 (GLOBE NEWSWIRE) Insmed Incorporated (Nasdaq: INSM), a global biophar
Read more →INSMInsmed to Host Third Quarter 2016 Financial Results Conference Call on Thursday, November 3, 2016
BRIDGEWATER, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its third quarter financial results on Thursday, November 3, 2016.
Read more →INSMInsmed Announces Publication of Phase 2 Study of ARIKAYCE in Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE’s potential to achieve early and sustained negative sputum cultures BRIDGEWATER, N.J., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company
Read more →INSMInsmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
BRIDGEWATER, N.J., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to A
Read more →INSMInsmed Appoints Roger Adsett as Chief Commercial Officer
BRIDGEWATER, N.J., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Roger Adsett as chief commercial officer. Mr. Adsett was most
Read more →INSMInsmed to Participate at September Investor Conferences
BRIDGEWATER, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking pla
Read more →INSMInsmed Announces Upcoming Presentations at European Respiratory Society 2016 International Congress
BRIDGEWATER, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that three INS1009-related abstracts were accepted for presentation at the European
Read more →INSMInsmed Reports Second Quarter 2016 Financial Results
BRIDGEWATER, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the quarter ended June 30, 2016. Global phase 3 CONVERT stud
Read more →INSMInsmed Announces Withdrawal of Marketing Authorization Application for ARIKAYCE™ in Europe
BRIDGEWATER, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has withdrawn its Marketing Authorization Application (MAA) from the Europ
Read more →INSMInsmed to Present at the Bank of America Global Healthcare Conference
BRIDGEWATER, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the Bank of America Global Healthcare Co
Read more →INSMInsmed Reports First Quarter 2016 Financial Results
BRIDGEWATER, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the quarter ended March 31, 2016. Global Phase 3 CONVERT stud
Read more →INSMInsmed Announces Upcoming Presentations at the American Thoracic Society 2016 International Meeting
BRIDGEWATER, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that three ARIKAYCE™-related abstracts and one treprostinil prodrug abstract were ac
Read more →INSMInsmed to Present at the 36th Annual Cowen & Company Healthcare Conference
BRIDGEWATER, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the 36th Annual Cowen & Company Health
Read more →INSMInsmed Reports Fourth Quarter 2015 Financial Results
BRIDGEWATER, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the fourth quarter and year ended December 31, 2015. Global
Read more →INSMInsmed to Present at the 34th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the 34th Annual J.P. Morgan Healthcare
Read more →INSMInsmed to Present at the Piper Jaffray 27th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that Will Lewis, president and chief executive officer of Insmed, will participate
Read more →INSMInsmed to Present at the Stifel 2015 Healthcare Conference
BRIDGEWATER, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the Stifel 2015 Healthcare Conference t
Read more →INSMInsmed Reports Third Quarter 2015 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the third quarter and nine months ended September 30, 2015.
Read more →INSMInsmed to Host Third Quarter 2015 Financial Results Conference Call on Friday, November 6, 2015
BRIDGEWATER, N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its financial results for the three and nine months ended September
Read more →INSMInsmed Announces Upcoming Data Presentation at AMCP Nexus 2015
BRIDGEWATER, N.J., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported new nontuberculous mycobacteria (NTM) lung disease research will be presented at the Acade
Read more →INSMINSMED Launches Comprehensive Educational Campaign to Raise Awareness of NTM Lung Disease
NTMfacts.com Provides a Dynamic Resource for Healthcare Providers to Learn More About NTM Lung Disease Through Patient Testimonials and Case Studies Launch of Campaign Coincides With American Thoracic Society’s NTM Week BRIDGEWATER, N.J., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Insme
Read more →INSMInsmed Announces Upcoming Data Presentations at Infectious Disease Week 2015
BRIDGEWATER, N.J., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today reported new nontuberculous mycobacteria (NTM) lung disease information will be presented at the I
Read more →INSMInsmed to Present at the Leerink Partners Rare Disease Roundtable
BRIDGEWATER, N.J., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today reported that company management will participate at the 2015 Leerink Partners Rare Disease Round
Read more →INSMInsmed Announces Upcoming Data Presentations at ERS 2015
BRIDGEWATER, N.J. , Sept. 22, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters will be presented at the Europ
Read more →INSMInsmed Announces Upcoming Data Presentations at ICAAC/ICC 2015
BRIDGEWATER, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported new nontuberculous mycobacteria (NTM) lung disease information and a pharmacokinetic anal
Read more →INSMInsmed Reports Second Quarter 2015 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 06, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today reported financial results for the second quarter and six months ended June 30, 2015. Second Quar
Read more →INSMInsmed to Host Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015
BRIDGEWATER, N.J., July 28, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its financial results for the three months ended June 30, 2015, bef
Read more →INSMInsmed to Present at 31st Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for...
MONMOUTH JUNCTION, N.J. , Dec. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases,
Read more →INSMInsmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , Nov. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CL inical E valuation of AR IKACE (CLEAR-108)
Read more →INSMInsmed To Present At Two Upcoming Investor Conferences Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , Nov. 12, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Will Lewis , President and Chief Executive Officer, will be
Read more →INSMInsmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...
MONMOUTH JUNCTION, N.J. , Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the third quarter
Read more →INSMInsmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler to the position of Chief Fina
Read more →INSMInsmed to Host 2012 Third Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from...
MONMOUTH JUNCTION, N.J. , Oct. 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, will host a conference call on Wednesday, Novem
Read more →INSMInsmed Announces Pricing of Approximately $26 Million Direct Public Offering Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from...
MONMOUTH JUNCTION, N.J. , Sept. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced that it has priced a direct pu
Read more →INSMInsmed to Present at Stifel Nicolaus 2012 Healthcare Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...
MONMOUTH JUNCTION, N.J. , Aug. 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten , Presi
Read more →INSMInsmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...
MONMOUTH JUNCTION, N.J. , Aug. 14, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten , Presi
Read more →INSMInsmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...
MONMOUTH JUNCTION, N.J. , Aug. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the second quarter
Read more →INSMPharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , Aug. 6, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its Board of Directors, effective
Read more →INSMInsmed Receives Second Composition Of Matter Patent For ARIKACE® Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , Aug. 2, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the U.S. Patent and Trademark Office has issued a new compos
Read more →INSMInsmed Announces Planned Departure Of Chief Financial Officer Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , July 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice President & Chief Financial Of
Read more →INSMInsmed to Host 2012 Second Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will...
MONMOUTH JUNCTION, N.J. , July 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will host a conference call on Tuesday, August 7 th , 2012, at 8:30 AM ET , to d
Read more →INSMInsmed To Present At JMP Securities 7th Annual Healthcare Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , July 10, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Renu Gupta , M.D., Executive Vice President of Development
Read more →INSMInsmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...
MONMOUTH JUNCTION, N.J. , July 2, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that it has entered into a loan agreement with Hercules Technolog
Read more →INSMInsmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase ...
MONMOUTH JUNCTION, N.J. , June 27, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patien
Read more →INSMInsmed Provides Corporate Update Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic...
MONMOUTH JUNCTION, N.J. , May 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal amikacin for inhalation). "Insme
Read more →INSMInsmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2...
MONMOUTH JUNCTION, N.J. , May 23, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, T reatment with A RIKACE to R ealize G reater E fficacy T rial (TAR
Read more →INSMInsmed Appoints Donald J. Hayden, Jr. as Executive Chairman Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman...
MONMOUTH JUNCTION, N.J. , May 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb , M.D. as the Lead
Read more →INSMInsmed Announces First Quarter 2012 Financial Results Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012. Key Recent...
MONMOUTH JUNCTION, N.J. , May 8, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012 . Key Recent Highlights: "We are pleased FDA has lifted the clinical hold on ARIKACE in CF p
Read more →INSMInsmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the...
MONMOUTH JUNCTION, N.J. , May 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation
Read more →INSMInsmed to Host 2012 First Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012, at 8:30 AM ET, to discuss...
MONMOUTH JUNCTION, N.J. , April 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012 , at 8:30 AM ET , to discuss its financial results for the first quarter of 2012. Insmed intends to i
Read more →INSMInsmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CLinical Evaluation of ARIKACE...
MONMOUTH JUNCTION, N.J. , April 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CL inical E valuation of AR IKACE phase 3 study (CLEAR-108) of ARIKACE® (liposomal amikacin for inhalation)
Read more →INSMInsmed Announces Fourth Quarter and Full-Year 2011 Financial Results Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31,...
MONMOUTH JUNCTION, N.J. , March 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011 . Key Recent Highlights: "We have recently made significant progres
Read more →INSMInsmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to...
MONMOUTH JUNCTION, N.J. , Feb. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012 , at 8:30 AM ET , to discuss its financial results for the fourth quarter and year-end 2011. Insmed
Read more →INSMInsmed Incorporated Provides Update on Clinical Program for ARIKACE® Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of...
MONMOUTH JUNCTION, N.J. , Feb. 10, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculou
Read more →INSMInsmed Incorporated Provides Corporate Update Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the...
MONMOUTH JUNCTION, N.J. , Jan. 20, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalati
Read more →INSMInsmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be...
MONMOUTH JUNCTION, N.J. , Nov. 14, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten , President and CEO of Insmed, will be presenting a corporate overview at the Lazard Capital Markets 8th Annual Healthc
Read more →INSMInsmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended...
MONMOUTH JUNCTION, N.J. , Nov. 8, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011 . Key Recent Highlights: "Insmed is currently undertaking a
Read more →INSMInsmed to Host 2011 Third Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8th, 2011, at 8:30 AM ET, to...
MONMOUTH JUNCTION, N.J. , Oct. 25, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8 th , 2011, at 8:30 AM ET , to discuss its financial results for the third quarter of 2011. Insmed intends
Read more →INSMInsmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug...
MONMOUTH JUNCTION, N.J. , Oct. 14, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed
Read more →INSMInsmed to Present at Sixth Annual JMP Securities Healthcare Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be...
MONMOUTH JUNCTION, N.J. , Sept. 26, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten , President and CEO of Insmed, will be presenting a corporate overview at the Sixth Annual JMP Securities Healthcare C
Read more →INSMInsmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be...
MONMOUTH JUNCTION, N.J. , Aug. 11, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten , President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush Securities Life Sciences Man
Read more →INSMInsmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011. ...
MONMOUTH JUNCTION, N.J. , Aug. 8, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011 . Key Recent Highlights: "We continue to believe Arikace™ has the potentia
Read more →INSMInsmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the ...
FDA has requested additional information on ARIKACE and data from the rat study. Insmed anticipates being able to supply the currently requested information and data within the next 30 days. As a result of the clinical hold, the Company has suspended initiation of the ARIKACE ph
Read more →INSMInsmed to Host 2011 Second Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Monday, August 8th, 2011, at 8:30 AM ET, to...
MONMOUTH JUNCTION, N.J. , July 26, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Monday, August 8th, 2011 , at 8:30 AM ET , to discuss its financial results for the second quarter of 2011. Insmed intends to
Read more →INSMAndrea Drucker Joins Insmed as General Counsel Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that Andrea ( Andi ) Holtzman Drucker, J.D. has been appointed to ...
MONMOUTH JUNCTION, N.J. , July 18, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that Andrea ("Andi") Holtzman Drucker , J.D. has been appointed to the newly created position of Senior Vice President, General Counsel and
Read more →INSMInsmed Announces its Addition to the Russell 3000® Index Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has been added to the Russell 3000® Index following...
MONMOUTH JUNCTION, N.J. , June 28, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has been added to the Russell 3000® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global
Read more →INSMInsmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total...
MONMOUTH JUNCTION, N.J. , June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE® (liposomal amikacin
Read more →INSMInsmed Announces First Quarter 2011 Financial Results Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011. Key Recent...
MONMOUTH JUNCTION, N.J. , May 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011 . Key Recent Highlights: "The first several months of the year have produced multiple suc
Read more →INSMInsmed to Host 2011 First Quarter Earnings Conference Call Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 10th, 2011, at 8:30 AM ET, to discuss ...
RICHMOND, Va. , April 26, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 10th, 2011 , at 8:30 AM ET , to discuss its financial results for the first quarter of 2011. Insmed intends to issue its
Read more →INSMInsmed Regains NASDAQ Compliance Insmed Incorporated (Nasdaq CM: INSMD), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market...
RICHMOND, Va. , March 21, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSMD), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requiremen
Read more →INSMInsmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to...
RICHMOND, Va. , March 21, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSMD ), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalati
Read more →INSMInsmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA)...
RICHMOND, Va. , March 3, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) fo
Read more →INSMOne-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the one-for-10 reverse stock split of Insmed's Common Stock...
RICHMOND, Va. , March 2, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that the one-for-10 reverse stock split of Insmed's Common Stock became effective as of 5:00 PM EST , on March 2, 2011 , after the State Corporation Com
Read more →INSMInsmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the...
RICHMOND, Va. , March 1, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the conversion of Insmed's Series B Conditional Convertible Preferred Stock (Series B Prefe
Read more →INSMInsmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President & CEO of Insmed, will participate on ...
RICHMOND, Va. , Feb. 24, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that Timothy Whitten , President & CEO of Insmed, will participate on the Phase III and Beyond panel as part of the 2011 RBC Capital Markets Healthcare
Read more →INSMInsmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that it will host a conference call on Thursday, March 10th, 2011,...
RICHMOND, Va. , Feb. 23, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that it will host a conference call on Thursday, March 10th, 2011 , at 8:30 AM EST , to discuss its financial results for the fourth quarter and year-en
Read more →INSMNASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it had received a letter, dated December 16, 2010, from The...
RICHMOND, Va. , Dec. 16, 2010 /PRNewswire-FirstCall/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it had received a letter, dated December 16, 2010 , from The NASDAQ Stock Market, notifying Insmed that it has been granted an addition
Read more →INSMInsmed Incorporated and Transave, Inc. Announce Business Combination Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it has entered into a business combination, effective...
RICHMOND, Va. , Dec. 2, 2010 /PRNewswire-FirstCall/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it has entered into a business combination, effective immediately, with Transave, Inc., a privately-held, NJ-based biopharmaceutical com
Read more →Competitive Position
How INSM ranks across every disease it competes inCompetitive Position is a premium feature
See how INSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial